Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05775523 · ClinicalTrials.gov registry record
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
A clinical trial of Growth Hormone Deficiency, sponsored by Ascendis Pharma Endocrinology Division A/S.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT05775523 is a study of Growth Hormone Deficiency that is actively recruiting participants, run by Ascendis Pharma Endocrinology Division A/S. The registered enrollment target is 500 participants, above the 356-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05775523, a study of Growth Hormone Deficiency, is actively recruiting participants, sponsored by Ascendis Pharma Endocrinology Division A/S.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
Conditions Studied
Interventions
- DRUG No intervention
Study Locations (20)
California
- Ascendis Investigational Site - Orange
- Ascendis Investigational Site - Sacramento
- Ascendis Investigational Site - San Francisco
Florida
- Ascendis Investigational Site - Orlando
- Ascendis Investigational Site - Orlando
- Ascendis Investigational Site - Tampa
New Hampshire
- Ascendis Investigational Site - Lebanon
- Ascendis Investigational Site - Manchester
Arizona
- Ascendis Investigational Site - Phoenix
Colorado
- Ascendis Pharma Investigational Site - Centennial
District of Columbia
- Ascendis Investigational Site - Washington D.C.
Georgia
- Ascendis Investigational Site - Sandy Springs
Idaho
- Ascendis Investigational Site - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2033-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05775523
The ClinicalTrials.gov registry entry for NCT05775523 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 356-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (40% higher). The listed sponsor is Ascendis Pharma Endocrinology Division A/S, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT05775523 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05775523 about?
NCT05775523 is a clinical study titled "A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin". The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
What is the current status of trial NCT05775523?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-03-20. Estimated completion is 2033-03.
What conditions does trial NCT05775523 study?
This clinical trial studies the following conditions: Growth Hormone Deficiency.
What interventions are being tested in trial NCT05775523?
The interventions under investigation include: No intervention (DRUG).
Who is sponsoring clinical trial NCT05775523?
This trial is sponsored by Ascendis Pharma Endocrinology Division A/S, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05775523 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Hormone Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
RECRUITING
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Chromosome 18 Clinical Research Center
RECRUITING
-
Growth Hormone Replacement Therapy for Retried Professional Football Players
RECRUITING · Phase 2
-
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
COMPLETED · Phase 2
-
Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.